Compare BLKB & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLKB | DAWN |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2004 | 2021 |
| Metric | BLKB | DAWN |
|---|---|---|
| Price | $45.11 | $21.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $60.00 | $26.00 |
| AVG Volume (30 Days) | 506.9K | ★ 5.4M |
| Earning Date | 05-13-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.32 | N/A |
| EPS | ★ 2.37 | N/A |
| Revenue | N/A | ★ $158,182,000.00 |
| Revenue This Year | $7.06 | $53.52 |
| Revenue Next Year | $3.48 | $27.10 |
| P/E Ratio | $19.00 | ★ N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $44.73 | $5.64 |
| 52 Week High | $74.86 | $21.40 |
| Indicator | BLKB | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 34.53 | 82.01 |
| Support Level | N/A | $6.40 |
| Resistance Level | $64.66 | N/A |
| Average True Range (ATR) | 1.72 | 0.63 |
| MACD | -0.01 | 1.18 |
| Stochastic Oscillator | 5.31 | 98.73 |
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.